US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ArriVent BioPharma

16.72

+1.6310.77%

Volume:3.71M

Turnover:61.16M

Market Cap:824.18M

PE:-4.52

High:17.35

Open:15.21

Low:14.97

Close:15.09

52wk High:35.83

52wk Low:11.36

Shares:49.31M

Float Shares:32.11M

Volume Ratio:0.85

T/O Rate:11.54%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.6975

EPS(LYR):-4.3239

ROE:-53.25%

ROA:-33.11%

PB:2.25

PE(LYR):-3.87

Loading ...

Overview Company News Filings

ArriVent BioPharma Price Target Cut to $29.00/Share from $42.00 by BTIG

ArriVent: Buy Rating Reaffirmed as Price Target Cut to $20 on Pipeline Update, ARR-217 Seen as Key Value Driver

Analysts’ Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)

US Research Roundup-Allstate, Caribou Biosciences, Zscaler

ArriVent Retains Buy Rating as Analyst Sees Upside from Broader Pipeline Despite Trial Miss, Cutting Price Target to $22

ArriVent Biopharma price target lowered to $18 from $45 at Jefferies

Top Midday Decliners

MT Newswires Live

Why This Biotech Stock is Having Its Worst Day Ever

Analyst Maintains Buy on ArriVent Despite Trial Setback, Trims Price Target to $15 Ahead of Key ADC Data

ArriVent BioPharma Down over 52%, on Track for Record Low Close and Record Percent Decrease

Arrivent Biopharma, Inc. : Guggenheim Cuts Target Price to $18 from $45

THOMSON REUTERS

ArriVent says Phase 3 firmonertinib trial did not meet endpoint

ArriVent BioPharma's Lung Cancer Drug Fails to Meet Primary Endpoint in Phase 3 Trial

ArriVent Falls After Lung Cancer Drug Misses Late-Stage Trial Goal

Arrivent Biopharma Shares Down 62.4% Premarket After Co's Lung Cancer Therapy Fails Late-Stage Trial

THOMSON REUTERS

ArriVent's Lung Cancer Treatment Fails Late-Stage Trial

ArriVent Says Phase 3 Furvent Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion NSCLC Misses Primary PFS Endpoint

Arrivent Biopharma, Inc.: a Trend Toward an Improvement in Overall Survival was Also Observed

THOMSON REUTERS

Arrivent Biopharma - Furvent Phase 3 Trial of Firmonertinib Does not Meet Primary Endpoint of Pfs by Bicr

THOMSON REUTERS

Arrivent Biopharma - Confirmed Orr by Bicr 60% for Firmonertinib 240Mg, 33% for Control

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/AVBP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AVBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","market":"US","secType":"STK","nameCN":"ArriVent BioPharma","latestPrice":16.715,"timestamp":1791402944627,"preClose":15.09,"halted":0,"volume":3706601,"delay":0,"changeRate":0.10768721007289596,"floatShares":32106300,"shares":49307729,"eps":-3.697539,"marketStatus":"Trading","change":1.625,"latestTime":"10-07 15:55:46 EDT","open":15.21,"high":17.345,"low":14.9677,"amount":61161021.849368006,"amplitude":0.157541,"askPrice":16.72,"askSize":448,"bidPrice":16.71,"bidSize":942,"shortable":0,"etf":0,"ttmEps":-3.697539,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791403200000},"marketStatusCode":2,"adr":0,"listingDate":1706245200000,"exchange":"NASDAQ","adjPreClose":15.09,"preHourTrading":{"tag":"盘前","latestPrice":15.21,"preClose":15.09,"latestTime":"09:29 EDT","volume":168164,"amount":2536139.468744,"timestamp":1791379799999,"change":0.12,"changeRate":0.007952,"amplitude":0.066249},"postHourTrading":{"tag":"盘后","latestPrice":14.9353,"preClose":15.09,"latestTime":"19:59 EDT","volume":44513,"amount":664290.4969,"timestamp":1791331195934,"change":-0.1547,"changeRate":-0.010252,"amplitude":0.035785},"volumeRatio":0.848869,"impliedVol":1.2221,"impliedVolPercentile":0.494},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","floatShares":32106300,"roa":"-33.11%","roe":"-53.25%","lyrEps":-4.323888,"volumeRatio":0.848869,"shares":49307729,"dividePrice":0,"high":17.345,"amplitude":0.157541,"preClose":15.09,"low":14.9677,"week52Low":11.36,"pbRate":"2.25","week52High":35.83,"institutionHeld":0,"latestPrice":16.715,"committee":0.355396,"eps":-3.697539,"divideRate":0,"volume":3706601,"delay":0,"ttmEps":-3.697539,"open":15.21,"prevYearClose":20.12,"prevWeekClose":28.27,"prevMonthClose":30.28,"prevQuarterClose":30.28,"fiveDayClose":30.28,"twentyDayClose":29.79,"sixtyDayClose":32.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"AVBP","fiscalQuarterEnding":"2026/06","expectedEps":-0.98,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-1.05},{"market":"US","date":"2026-05-11","symbol":"AVBP","fiscalQuarterEnding":"2026/03","expectedEps":-0.88,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-0.96},{"market":"US","date":"2026-03-05","symbol":"AVBP","fiscalQuarterEnding":"2025/12","expectedEps":-0.87,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.78},{"market":"US","date":"2025-11-10","symbol":"AVBP","fiscalQuarterEnding":"2025/09","expectedEps":-0.78,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.83},{"market":"US","date":"2025-08-11","symbol":"AVBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.7,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"pre","actualEps":-0.9}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4167,"buy":0.5833,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1766462400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVBP","date":"2026-10-06","current":-4.520574,"percent":0.484756,"low":-15.980041,"twenty":-10.953584,"median":-8.456747,"eighty":-6.06383,"high":-4.80343,"avg":-8.593194,"sd":2.424276,"marketCap":1403297967},"quantilePoints":[{"date":"2024-01-26","current":-15.452095,"twenty":-15.452095,"median":-15.452095,"eighty":-15.452095,"marketCap":905214654},{"date":"2024-02-02","current":-11.990156,"twenty":-12.001066,"median":-11.872873,"eighty":-10.91006,"marketCap":702407320},{"date":"2024-02-09","current":-12.548731,"twenty":-12.548731,"median":-12.001066,"eighty":-11.75559,"marketCap":735129780},{"date":"2024-02-16","current":-12.588659,"twenty":-12.548731,"median":-12.126596,"eighty":-11.919241,"marketCap":737468829},{"date":"2024-02-23","current":-11.219707,"twenty":-12.556717,"median":-11.998256,"eighty":-11.67237,"marketCap":657272853},{"date":"2024-03-01","current":-12.286349,"twenty":-12.548731,"median":-11.990156,"eighty":-11.204877,"marketCap":719758884},{"date":"2024-03-08","current":-11.464977,"twenty":-12.548731,"median":-11.964074,"eighty":-11.315533,"marketCap":671641299},{"date":"2024-03-15","current":-10.59227,"twenty":-12.5031,"median":-11.767288,"eighty":-11.121598,"marketCap":620516364},{"date":"2024-03-22","current":-10.386927,"twenty":-12.327418,"median":-11.658912,"eighty":-10.920492,"marketCap":608486967},{"date":"2024-03-28","current":-10.267144,"twenty":-12.279504,"median":-11.507757,"eighty":-10.718898,"marketCap":601469820},{"date":"2024-04-05","current":-8.84046,"twenty":-12.261251,"median":-11.265338,"eighty":-10.410884,"marketCap":612935625},{"date":"2024-04-12","current":-8.536116,"twenty":-12.10149,"median":-11.165519,"eighty":-9.961411,"marketCap":591834562},{"date":"2024-04-19","current":-7.487821,"twenty":-11.997694,"median":-11.025772,"eighty":-8.805678,"marketCap":519153125},{"date":"2024-04-26","current":-7.507145,"twenty":-11.992272,"median":-10.91658,"eighty":-8.501334,"marketCap":520492875},{"date":"2024-05-03","current":-8.115832,"twenty":-11.986485,"median":-10.803317,"eighty":-8.191193,"marketCap":562695000},{"date":"2024-05-10","current":-8.079495,"twenty":-11.960082,"median":-10.543786,"eighty":-8.115832,"marketCap":602552562},{"date":"2024-05-17","current":-9.049573,"twenty":-11.929189,"median":-10.386927,"eighty":-8.101297,"marketCap":674899062},{"date":"2024-05-24","current":-8.479203,"twenty":-11.828069,"median":-10.210104,"eighty":-8.115832,"marketCap":632362000},{"date":"2024-05-31","current":-8.739687,"twenty":-11.762609,"median":-9.361752,"eighty":-8.133223,"marketCap":651788375},{"date":"2024-06-07","current":-8.241175,"twenty":-11.7192,"median":-8.959751,"eighty":-8.180566,"marketCap":614610312},{"date":"2024-06-14","current":-8.456747,"twenty":-11.662334,"median":-8.912923,"eighty":-8.216398,"marketCap":630687312},{"date":"2024-06-21","current":-7.455231,"twenty":-11.653208,"median":-8.84046,"eighty":-8.15931,"marketCap":555996250},{"date":"2024-06-28","current":-7.81452,"twenty":-11.61214,"median":-8.79358,"eighty":-8.133223,"marketCap":582791250},{"date":"2024-07-05","current":-8.205246,"twenty":-11.533425,"median":-8.753505,"eighty":-8.152944,"marketCap":611930812},{"date":"2024-07-12","current":-8.268121,"twenty":-11.43988,"median":-8.706383,"eighty":-8.152944,"marketCap":616619937},{"date":"2024-07-15","current":-8.259139,"twenty":-11.414782,"median":-8.695535,"eighty":-8.154535,"marketCap":615950062},{"date":"2024-08-02","current":-9.655872,"twenty":-11.389685,"median":-8.706383,"eighty":-8.156127,"marketCap":720115625},{"date":"2024-08-09","current":-10.262171,"twenty":-11.294999,"median":-8.753505,"eighty":-8.186872,"marketCap":765332187},{"date":"2024-08-16","current":-10.701201,"twenty":-11.237959,"median":-8.81702,"eighty":-8.205246,"marketCap":801359406},{"date":"2024-08-23","current":-10.705686,"twenty":-11.199173,"median":-8.912923,"eighty":-8.209568,"marketCap":801695265},{"date":"2024-08-30","current":-12.010819,"twenty":-11.389685,"median":-8.993434,"eighty":-8.224295,"marketCap":899430214},{"date":"2024-09-06","current":-11.93009,"twenty":-11.657877,"median":-9.253918,"eighty":-8.235785,"marketCap":893384753},{"date":"2024-09-13","current":-10.669806,"twenty":-11.694732,"median":-9.655872,"eighty":-8.248361,"marketCap":799008394},{"date":"2024-09-20","current":-10.85369,"twenty":-11.663166,"median":-9.763659,"eighty":-8.262732,"marketCap":812778610},{"date":"2024-09-27","current":-10.544226,"twenty":-11.657877,"median":-10.060071,"eighty":-8.269917,"marketCap":789604344},{"date":"2024-10-04","current":-11.49056,"twenty":-11.61214,"median":-10.208101,"eighty":-8.279798,"marketCap":860470578},{"date":"2024-10-11","current":-12.463804,"twenty":-11.739278,"median":-10.315491,"eighty":-8.299559,"marketCap":933351966},{"date":"2024-10-18","current":-13.002004,"twenty":-11.938503,"median":-10.371883,"eighty":-8.317243,"marketCap":973655038},{"date":"2024-10-25","current":-13.912458,"twenty":-11.99333,"median":-10.426855,"eighty":-8.325491,"marketCap":1041834400},{"date":"2024-10-31","current":-14.114283,"twenty":-12.114871,"median":-10.539741,"eighty":-8.328911,"marketCap":1056948052},{"date":"2024-11-08","current":-15.980041,"twenty":-12.249611,"median":-10.573379,"eighty":-8.330997,"marketCap":1196665367},{"date":"2024-11-15","current":-11.674764,"twenty":-12.282511,"median":-10.59227,"eighty":-8.332793,"marketCap":946216280},{"date":"2024-11-22","current":-11.05527,"twenty":-12.272349,"median":-10.669806,"eighty":-8.342492,"marketCap":896007510},{"date":"2024-11-29","current":-12.456408,"twenty":-12.274941,"median":-10.685503,"eighty":-8.352544,"marketCap":1009566943},{"date":"2024-12-06","current":-11.870175,"twenty":-12.284404,"median":-10.712096,"eighty":-8.353452,"marketCap":962053946},{"date":"2024-12-13","current":-10.760075,"twenty":-12.274941,"median":-10.748293,"eighty":-8.371867,"marketCap":872082526},{"date":"2024-12-20","current":-10.664448,"twenty":-12.261979,"median":-10.759506,"eighty":-8.380399,"marketCap":864332179},{"date":"2024-12-27","current":-11.46688,"twenty":-12.254096,"median":-10.803317,"eighty":-8.380399,"marketCap":929367700},{"date":"2025-01-03","current":-11.421146,"twenty":-12.244582,"median":-10.85369,"eighty":-8.380399,"marketCap":925661012},{"date":"2025-01-10","current":-11.167527,"twenty":-12.234172,"median":-10.860965,"eighty":-8.382195,"marketCap":905105744},{"date":"2025-01-17","current":-10.177999,"twenty":-12.217129,"median":-10.850538,"eighty":-8.390279,"marketCap":824906501},{"date":"2025-01-24","current":-11.329677,"twenty":-12.196013,"median":-10.850538,"eighty":-8.405549,"marketCap":918247637},{"date":"2025-01-31","current":-12.09469,"twenty":-12.164539,"median":-10.860965,"eighty":-8.437266,"marketCap":980250413},{"date":"2025-02-07","current":-11.383727,"twenty":-12.161213,"median":-10.897572,"eighty":-8.450678,"marketCap":922628268},{"date":"2025-02-14","current":-11.16337,"twenty":-12.157147,"median":-10.9231,"eighty":-8.461238,"marketCap":904768772},{"date":"2025-02-21","current":-11.387884,"twenty":-12.140884,"median":-10.92545,"eighty":-8.479203,"marketCap":922965239},{"date":"2025-02-28","current":-9.8537,"twenty":-12.107163,"median":-10.91658,"eighty":-8.519623,"marketCap":798622715},{"date":"2025-03-07","current":-9.217439,"twenty":-12.09469,"median":-10.885085,"eighty":-8.536116,"marketCap":741893256},{"date":"2025-03-14","current":-9.192082,"twenty":-12.065586,"median":-10.857328,"eighty":-8.618427,"marketCap":739852284},{"date":"2025-03-21","current":-8.258082,"twenty":-12.010819,"median":-10.847386,"eighty":-8.519623,"marketCap":664676489},{"date":"2025-03-28","current":-7.848136,"twenty":-12.001066,"median":-10.781696,"eighty":-8.449161,"marketCap":631680778},{"date":"2025-04-04","current":-7.159258,"twenty":-11.995446,"median":-10.737081,"eighty":-8.380399,"marketCap":576234377},{"date":"2025-04-11","current":-7.125448,"twenty":-11.990156,"median":-10.711139,"eighty":-8.353452,"marketCap":573513081},{"date":"2025-04-17","current":-7.564978,"twenty":-11.988746,"median":-10.703443,"eighty":-8.330997,"marketCap":608889926},{"date":"2025-04-25","current":-8.94696,"twenty":-11.984909,"median":-10.669806,"eighty":-8.330476,"marketCap":720122890},{"date":"2025-05-02","current":-8.908923,"twenty":-11.976101,"median":-10.6604,"eighty":-8.330997,"marketCap":717061432},{"date":"2025-05-09","current":-8.353948,"twenty":-11.95416,"median":-10.580862,"eighty":-8.330997,"marketCap":672392561},{"date":"2025-05-16","current":-5.164444,"twenty":-11.945123,"median":-10.566696,"eighty":-8.323142,"marketCap":658249673},{"date":"2025-05-23","current":-5.537551,"twenty":-11.932894,"median":-10.539741,"eighty":-8.281274,"marketCap":705805133},{"date":"2025-05-30","current":-5.636867,"twenty":-11.923581,"median":-10.506711,"eighty":-8.258716,"marketCap":718463781},{"date":"2025-06-06","current":-6.29987,"twenty":-11.889801,"median":-10.45834,"eighty":-8.241176,"marketCap":802968806},{"date":"2025-06-13","current":-6.342817,"twenty":-11.86768,"median":-10.37894,"eighty":-8.205246,"marketCap":808442816},{"date":"2025-06-20","current":-6.681029,"twenty":-11.831093,"median":-10.360937,"eighty":-8.13004,"marketCap":851550643},{"date":"2025-06-27","current":-6.122711,"twenty":-11.774139,"median":-10.336565,"eighty":-8.056606,"marketCap":780388516},{"date":"2025-07-03","current":-5.951741,"twenty":-11.764948,"median":-10.291317,"eighty":-8.012114,"marketCap":758596999},{"date":"2025-07-11","current":-6.3128,"twenty":-11.752729,"median":-10.177999,"eighty":-7.877518,"marketCap":804616846},{"date":"2025-07-18","current":-6.510523,"twenty":-11.737545,"median":-10.15098,"eighty":-7.814365,"marketCap":829818191},{"date":"2025-07-25","current":-6.146598,"twenty":-11.721024,"median":-10.060071,"eighty":-7.74746,"marketCap":783433107},{"date":"2025-08-01","current":-5.590682,"twenty":-11.706801,"median":-9.819907,"eighty":-7.667253,"marketCap":712577152},{"date":"2025-08-08","current":-5.312724,"twenty":-11.672734,"median":-9.759167,"eighty":-7.57343,"marketCap":677149175},{"date":"2025-08-15","current":-5.522288,"twenty":-11.663891,"median":-9.64689,"eighty":-7.464633,"marketCap":755393737},{"date":"2025-08-22","current":-5.895976,"twenty":-11.659587,"median":-9.496371,"eighty":-7.205647,"marketCap":806510606},{"date":"2025-08-29","current":-5.697269,"twenty":-11.653822,"median":-9.38434,"eighty":-6.898922,"marketCap":779329414},{"date":"2025-09-05","current":-5.789208,"twenty":-11.653208,"median":-9.260758,"eighty":-6.705187,"marketCap":791905786},{"date":"2025-09-12","current":-5.640919,"twenty":-11.550537,"median":-9.192082,"eighty":-6.342817,"marketCap":771621314},{"date":"2025-09-19","current":-5.510425,"twenty":-11.49056,"median":-9.038346,"eighty":-6.3128,"marketCap":753770979},{"date":"2025-09-26","current":-5.092249,"twenty":-11.46688,"median":-8.984996,"eighty":-6.266951,"marketCap":696568768},{"date":"2025-10-03","current":-5.584569,"twenty":-11.464977,"median":-8.939882,"eighty":-6.203238,"marketCap":763913215},{"date":"2025-10-10","current":-6.266699,"twenty":-11.458565,"median":-8.908923,"eighty":-6.178119,"marketCap":857221786},{"date":"2025-10-17","current":-5.820349,"twenty":-11.441934,"median":-8.860202,"eighty":-6.17476,"marketCap":796165526},{"date":"2025-10-24","current":-5.365101,"twenty":-11.433619,"median":-8.84046,"eighty":-6.120027,"marketCap":733892196},{"date":"2025-10-31","current":-5.477801,"twenty":-11.433619,"median":-8.796928,"eighty":-6.098553,"marketCap":749308395},{"date":"2025-11-07","current":-5.454075,"twenty":-11.421146,"median":-8.757651,"eighty":-5.987916,"marketCap":746062880},{"date":"2025-11-14","current":-5.38103,"twenty":-11.41283,"median":-8.728459,"eighty":-5.931566,"marketCap":812417184},{"date":"2025-11-21","current":-5.484932,"twenty":-11.400357,"median":-8.689159,"eighty":-5.895976,"marketCap":828104101},{"date":"2025-11-28","current":-6.2724,"twenty":-11.397031,"median":-8.627903,"eighty":-5.884113,"marketCap":946994421},{"date":"2025-12-05","current":-6.657931,"twenty":-11.389547,"median":-8.556032,"eighty":-5.884113,"marketCap":1005201140},{"date":"2025-12-12","current":-6.649728,"twenty":-11.384558,"median":-8.523142,"eighty":-5.893603,"marketCap":1003962699},{"date":"2025-12-19","current":-5.788435,"twenty":-11.375905,"median":-8.467975,"eighty":-5.893603,"marketCap":873926412},{"date":"2025-12-26","current":-6.094673,"twenty":-11.359859,"median":-8.441726,"eighty":-5.901564,"marketCap":920161536},{"date":"2026-01-02","current":-5.501338,"twenty":-11.346075,"median":-8.391627,"eighty":-5.884113,"marketCap":830580983},{"date":"2026-01-09","current":-5.364625,"twenty":-11.337228,"median":-8.380399,"eighty":-5.844354,"marketCap":809940302},{"date":"2026-01-16","current":-5.988037,"twenty":-11.332171,"median":-8.373482,"eighty":-5.835858,"marketCap":904061805},{"date":"2026-01-23","current":-6.890344,"twenty":-11.326351,"median":-8.3537,"eighty":-5.833294,"marketCap":1040290297},{"date":"2026-01-30","current":-6.152093,"twenty":-11.304731,"median":-8.339979,"eighty":-5.843953,"marketCap":928830622},{"date":"2026-02-06","current":-5.837652,"twenty":-11.270243,"median":-8.329694,"eighty":-5.843953,"marketCap":881357057},{"date":"2026-02-13","current":-6.130218,"twenty":-11.263238,"median":-8.321475,"eighty":-5.843953,"marketCap":925528113},{"date":"2026-02-20","current":-6.313414,"twenty":-11.254838,"median":-8.290577,"eighty":-5.845558,"marketCap":953186625},{"date":"2026-02-27","current":-6.351694,"twenty":-11.246523,"median":-8.270367,"eighty":-5.848589,"marketCap":958966016},{"date":"2026-03-06","current":-6.710988,"twenty":-11.219707,"median":-8.258082,"eighty":-5.878182,"marketCap":1116090955},{"date":"2026-03-13","current":-6.40401,"twenty":-11.204946,"median":-8.245403,"eighty":-5.8814,"marketCap":1065038082},{"date":"2026-03-20","current":-6.07577,"twenty":-11.192473,"median":-8.232192,"eighty":-5.884113,"marketCap":1010449078},{"date":"2026-03-27","current":-5.79537,"twenty":-11.188316,"median":-8.205246,"eighty":-5.878182,"marketCap":963816367},{"date":"2026-04-02","current":-6.437233,"twenty":-11.18605,"median":-8.155331,"eighty":-5.851728,"marketCap":1070563284},{"date":"2026-04-10","current":-7.242551,"twenty":-11.184423,"median":-8.115832,"eighty":-5.873048,"marketCap":1204494199},{"date":"2026-04-17","current":-7.869796,"twenty":-11.184158,"median":-8.05762,"eighty":-5.880756,"marketCap":1308810027},{"date":"2026-04-24","current":-8.239233,"twenty":-11.170853,"median":-8.079495,"eighty":-5.88357,"marketCap":1370250282},{"date":"2026-05-01","current":-8.263153,"twenty":-11.164201,"median":-8.071094,"eighty":-5.884113,"marketCap":1374228427},{"date":"2026-05-08","current":-8.043687,"twenty":-11.160044,"median":-8.062693,"eighty":-5.892853,"marketCap":1337729551},{"date":"2026-05-15","current":-9.113539,"twenty":-11.148286,"median":-8.082287,"eighty":-5.895788,"marketCap":1323659453},{"date":"2026-05-22","current":-8.658182,"twenty":-11.130931,"median":-8.115832,"eighty":-5.903426,"marketCap":1257523056},{"date":"2026-05-29","current":-8.648562,"twenty":-11.121131,"median":-8.15931,"eighty":-5.909002,"marketCap":1256125808},{"date":"2026-06-05","current":-10.611083,"twenty":-11.112406,"median":-8.208286,"eighty":-5.914633,"marketCap":1541164367},{"date":"2026-06-12","current":-9.684337,"twenty":-11.089363,"median":-8.224914,"eighty":-5.923855,"marketCap":1406562825},{"date":"2026-06-18","current":-10.056318,"twenty":-11.074395,"median":-8.233917,"eighty":-5.929786,"marketCap":1460589742},{"date":"2026-06-26","current":-10.846778,"twenty":-11.071901,"median":-8.241176,"eighty":-5.939636,"marketCap":1575396939},{"date":"2026-07-02","current":-11.063233,"twenty":-11.071901,"median":-8.253856,"eighty":-5.951741,"marketCap":1606835016},{"date":"2026-07-10","current":-10.797074,"twenty":-11.071901,"median":-8.258372,"eighty":-5.954231,"marketCap":1568177825},{"date":"2026-07-17","current":-10.505261,"twenty":-11.071901,"median":-8.265637,"eighty":-5.966771,"marketCap":1525794641},{"date":"2026-07-24","current":-10.11404,"twenty":-11.070167,"median":-8.283439,"eighty":-5.979263,"marketCap":1468973229},{"date":"2026-07-31","current":-9.831847,"twenty":-11.063233,"median":-8.313032,"eighty":-5.987916,"marketCap":1427987292},{"date":"2026-08-07","current":-9.944083,"twenty":-11.060026,"median":-8.325975,"eighty":-5.988037,"marketCap":1444288517},{"date":"2026-08-14","current":-9.008172,"twenty":-11.059428,"median":-8.330997,"eighty":-5.993847,"marketCap":1479231870},{"date":"2026-08-21","current":-8.761948,"twenty":-11.05527,"median":-8.347715,"eighty":-5.99759,"marketCap":1438799532},{"date":"2026-08-28","current":-9.308444,"twenty":-11.025772,"median":-8.353948,"eighty":-6.007177,"marketCap":1528539599},{"date":"2026-09-04","current":-9.317452,"twenty":-11.021545,"median":-8.377748,"eighty":-6.007177,"marketCap":1530018830},{"date":"2026-09-11","current":-8.617818,"twenty":-11.020363,"median":-8.380399,"eighty":-6.015927,"marketCap":1415131822},{"date":"2026-09-18","current":-8.515725,"twenty":-11.011642,"median":-8.38489,"eighty":-6.022488,"marketCap":1398367194},{"date":"2026-09-25","current":-9.038199,"twenty":-11.006851,"median":-8.398491,"eighty":-6.041944,"marketCap":1484162642},{"date":"2026-10-02","current":-8.68688,"twenty":-10.96973,"median":-8.449161,"eighty":-6.059291,"marketCap":1426472599},{"date":"2026-10-06","current":-8.545752,"twenty":-10.953584,"median":-8.456747,"eighty":-6.06383,"marketCap":1403297967}],"updateTime":1791402946227},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVBP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673001880","title":"ArriVent BioPharma Price Target Cut to $29.00/Share from $42.00 by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2673001880","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673001880?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:13","pubTimestamp":1791375180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673909452","title":"ArriVent: Buy Rating Reaffirmed as Price Target Cut to $20 on Pipeline Update, ARR-217 Seen as Key Value Driver","url":"https://stock-news.laohu8.com/highlight/detail?id=2673909452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673909452?lang=en_us&edition=fundamental","pubTime":"2026-10-07 17:55","pubTimestamp":1791366922,"startTime":"0","endTime":"0","summary":"Citi analyst Yigal Nochomovitz assigned a Buy rating on ArriVent BioPharma, Inc. yesterday and set a price target of $20.00. Yigal Nochomovitz has ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arrivent-buy-rating-reaffirmed-as-price-target-cut-to-20-on-pipeline-update-arr-217-seen-as-key-value-driver-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arrivent-buy-rating-reaffirmed-as-price-target-cut-to-20-on-pipeline-update-arr-217-seen-as-key-value-driver-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673509465","title":"Analysts’ Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673509465","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673509465?lang=en_us&edition=fundamental","pubTime":"2026-10-07 17:50","pubTimestamp":1791366612,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ArriVent BioPharma, Inc. (AVBP), Definium Therapeuti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-arrivent-biopharma-inc-avbp-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-arrivent-biopharma-inc-avbp-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","HCSG","BK4139","BK4585","AVBP","BK4588","LU0029874061.USD","XBI","DFTX","LABU","BK4581","LU0128526141.USD","BK4137","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673009523","title":"US Research Roundup-Allstate, Caribou Biosciences, Zscaler","url":"https://stock-news.laohu8.com/highlight/detail?id=2673009523","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673009523?lang=en_us&edition=fundamental","pubTime":"2026-10-07 15:36","pubTimestamp":1791358582,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Allstate, Caribou Biosciences, ZscalerOct 7 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Allstate Cor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nL4N45T0H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ISPR","ALL","ADAM","BCDF","FLUT","AXP","AMBQ","FNF","ZS","MIAX","GXPE","IGE","LW","MRVL","IYE","COIO","IBP","MAS","CBOE","EFC","HE","COP","CNM","MDU","COF","MFA","BLDR","EXEL","AGNC","FAF","ODDZ","CME","MRVU","AIS","AVBP","ALLY","DX","MHK","NLY","CIM","CACC","FBIN","FERG","COIW","ICE","NSLR","DVDN","LOB","GILD","COIN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673063538","title":"ArriVent Retains Buy Rating as Analyst Sees Upside from Broader Pipeline Despite Trial Miss, Cutting Price Target to $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2673063538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673063538?lang=en_us&edition=fundamental","pubTime":"2026-10-07 03:55","pubTimestamp":1791316530,"startTime":"0","endTime":"0","summary":"Analyst Boris Peaker from JonesTrading reiterated a Buy rating on ArriVent BioPharma, Inc. and decreased the price target to $22.00 from $45.00. Bo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arrivent-retains-buy-rating-as-analyst-sees-upside-from-broader-pipeline-despite-trial-miss-cutting-price-target-to-22-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arrivent-retains-buy-rating-as-analyst-sees-upside-from-broader-pipeline-despite-trial-miss-cutting-price-target-to-22-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673068914","title":"ArriVent Biopharma price target lowered to $18 from $45 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2673068914","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673068914?lang=en_us&edition=fundamental","pubTime":"2026-10-07 02:25","pubTimestamp":1791311118,"startTime":"0","endTime":"0","summary":"Jefferies lowered the firm’s price target on ArriVent Biopharma (AVBP) to $18 from $45 and keeps a Buy rating on the shares after the company annou...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrivent-biopharma-price-target-lowered-to-18-from-45-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrivent-biopharma-price-target-lowered-to-18-from-45-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673685530","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2673685530","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673685530?lang=en_us&edition=fundamental","pubTime":"2026-10-07 02:19","pubTimestamp":1791310749,"startTime":"0","endTime":"0","summary":"Seagate Technology  and Toshiba are competing to acquire TDK's magnetic-head business for hard-disk drives in a deal that could be worth several billion dollars, Bloomberg reported, citing people familiar with the matter.Shares declined 9.5%, with intraday trading volume rising to over 5.2 million from a daily average of about 4.6 million.ArriVent BioPharma  said its phase 3 trial of firmonertinib did not achieve its primary progression-free survival goal in previously untreated patients with EGFR exon 20 insertion-mutated non-small cell lung cancer.Shares sank 48% as intraday trading volume soared to over 14.1 million from a daily average of roughly 525,000.NFT  shares slumped 70% after the company priced a direct offering to raise around $2.55 million.Intraday trading volume was over 4.6 million shares, versus a daily average of about 2.7 million.Price: 804.50, Change: -82.59, Percent Change: -9.31","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DRMY","QQQG","IE00B19Z9Z06.USD","LU1670628061.USD","STXL","BK4512","BK4170","STX","LU0203345920.USD","QQQA","TTDKF","BK4585","DISK","IE00B894F039.SGD","LU1670627923.USD","STXU","BK4139","BK4077","MI","LU1983260115.SGD","AVBP","BK4588","LU0203347892.USD","BK4148","RULE","FCUS","IE00B19Z9P08.USD","STXX","EGGY","WLDR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673604057","title":"Why This Biotech Stock is Having Its Worst Day Ever","url":"https://stock-news.laohu8.com/highlight/detail?id=2673604057","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673604057?lang=en_us&edition=fundamental","pubTime":"2026-10-06 23:53","pubTimestamp":1791301980,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma stock declined sharply on Tuesday after the biopharmaceutical company published disappointing results for its lung-cancer drug.Shares of ArriVent BioPharma plunged 54% to $13, on pa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","AVBP","BK4581","BK4139","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673605730","title":"Analyst Maintains Buy on ArriVent Despite Trial Setback, Trims Price Target to $15 Ahead of Key ADC Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2673605730","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673605730?lang=en_us&edition=fundamental","pubTime":"2026-10-06 23:35","pubTimestamp":1791300918,"startTime":"0","endTime":"0","summary":"Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on ArriVent BioPharma, Inc.. The associated price target was lowered to $15...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-arrivent-despite-trial-setback-trims-price-target-to-15-ahead-of-key-adc-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-arrivent-despite-trial-setback-trims-price-target-to-15-ahead-of-key-adc-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673052419","title":"ArriVent BioPharma Down over 52%, on Track for Record Low Close and Record Percent Decrease","url":"https://stock-news.laohu8.com/highlight/detail?id=2673052419","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673052419?lang=en_us&edition=fundamental","pubTime":"2026-10-06 23:07","pubTimestamp":1791299220,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma, Inc.  is currently at $13.49, down $14.97 or 52.61%--Would be new all-time closing low --Would be largest percent decrease on record --Currently down three of the past four days--Down 32.97% year-to-date; on pace for worst year on record --Down 62.15% from its all-time closing high of $35.63 on Nov. 7, 2024--Down 30.16% from 52 weeks ago , when it closed at $19.31--Down 61.18% from its 52-week closing high of $34.74 on June 30, 2026--Would be a new 52-week closing low--Traded as low as $11.36; new all-time intraday low --Down 60.08% at today's intraday low; largest intraday percent decrease on record All data as of 11:05:10 AM ETSource: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673524500","title":"Arrivent Biopharma, Inc. : Guggenheim Cuts Target Price to $18 from $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2673524500","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673524500?lang=en_us&edition=fundamental","pubTime":"2026-10-06 23:06","pubTimestamp":1791299211,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nFWN45S1L3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051961","title":"ArriVent says Phase 3 firmonertinib trial did not meet endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051961","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673051961?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:13","pubTimestamp":1791292413,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) announced that the FURVENT Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, loca...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrivent-says-phase-3-firmonertinib-trial-did-not-meet-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrivent-says-phase-3-firmonertinib-trial-did-not-meet-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","AVBP","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673059400","title":"ArriVent BioPharma's Lung Cancer Drug Fails to Meet Primary Endpoint in Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673059400","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673059400?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:52","pubTimestamp":1791291120,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma said a treatment it's developing for a type of lung cancer failed to meet the primary endpoint in a Phase 3 trial.The stock slid 59% to $11.77 in premarket trading on Tuesday. At Mo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"ArriVent BioPharma's Lung Cancer Drug Fails to Meet Primary Endpoint in Phase 3 Trial","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673931059","title":"ArriVent Falls After Lung Cancer Drug Misses Late-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2673931059","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673931059?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:40","pubTimestamp":1791290420,"startTime":"0","endTime":"0","summary":"BUZZ-ArriVent falls after lung cancer drug misses late-stage trial goal** Shares of drug developer ArriVent BioPharmaAVBP.Ofall 62.7% to $10.62 premarket** Co says its experimental drug firmonertinibf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nL4N45S0VS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673605954","title":"Arrivent Biopharma Shares Down 62.4% Premarket After Co's Lung Cancer Therapy Fails Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673605954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673605954?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:36","pubTimestamp":1791290211,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nFWN45R1M5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673056964","title":"ArriVent's Lung Cancer Treatment Fails Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673056964","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673056964?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:07","pubTimestamp":1791288455,"startTime":"0","endTime":"0","summary":"ArriVent's lung cancer treatment fails late-stage trialOct 6 (Reuters)-ArriVent BioPharmaAVBP.Osaid on Tuesday its therapy to treat patients with a type of lung cancer did not meet the main goal in a late-stage trial.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nL4N45S0TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673056995","title":"ArriVent Says Phase 3 Furvent Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion NSCLC Misses Primary PFS Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2673056995","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673056995?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:07","pubTimestamp":1791288439,"startTime":"0","endTime":"0","summary":"ArriVent says Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC misses primary PFS endpointArriVent reported its Phase 3 FURVENT trial of firmonertinib in first-line EG","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDLbyN8Kn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014013.SGD","SG9999014021.USD","SG9999014039.USD","LU2095319765.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BCDF","IE00B64PRP62.GBP","AVBP","IE00BQXX3F31.USD","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","IE00BQXX3C00.GBP","NDAQ","BK4585","SG9999014005.SGD","BK4139","BK4112","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673705636","title":"Arrivent Biopharma, Inc.: a Trend Toward an Improvement in Overall Survival was Also Observed","url":"https://stock-news.laohu8.com/highlight/detail?id=2673705636","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673705636?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA87SF6V:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673568190","title":"Arrivent Biopharma - Furvent Phase 3 Trial of Firmonertinib Does not Meet Primary Endpoint of Pfs by Bicr","url":"https://stock-news.laohu8.com/highlight/detail?id=2673568190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673568190?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA87SF6V:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673305681","title":"Arrivent Biopharma - Confirmed Orr by Bicr 60% for Firmonertinib 240Mg, 33% for Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2673305681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673305681?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA87SF6V:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":69,"code":"91000000","status":"200"}]}}